Table 2.
Studies showing the major outcomes for hepatic sarcoidosis after drug therapy and number of liver transplantation.
| Reference | Population | Drug Therapy | Outcomes | Liver Transplant |
|---|---|---|---|---|
| Graf et al. [40] | n = 62 (f = 51.6%, m = 80.6%) |
Glucocorticoids (n = 43) Ursodeoxycholic acid (n = 25) MTX (n = 9) MMF (n = 1) CMF (n = 2) Infliximab (n = 1) |
Patients who needed a second-line immunosuppressive (n = 17) Deaths for liver-related complications (n = 3) |
n = 0 |
| Kennedy et al. [41] | n = 180 (f = 89, m = 91) |
Glucocorticoids, MTX, MMF or CMF Infliximab |
Patients who received a second-line immunosuppressive (n = 16) | n = 6 |
| Sedki et al. [42] | n = 286 (f = 223, m = 63 |
Glucocorticoids (n = 17) MTX, MMF or CMF (n = 15) Infliximab (n = 5) |
Patients who responded well to treatment with normalization of liver biochemistries (n = 18) Deaths for liver-related complications (n = 0) |
n = 2 |
f = females. m = males, MMF = mycophenolate, CMF = cyclophosphamide, MTX = methotrexate.